— Cardinal Health (NYSE: CAH) reported second-quarter 2020 non-GAAP EPS attributable to the company of $1.52 vs. $1.22 expected. — Revenue increased 5% to $39.7 billion vs. $39.43 billion expected. — GAAP EPS attributable to the company decreased to $0.75 from $0.93 in the second quarter of 2019. — For FY20, Cardinal Health lifted non-GAAP […]
“— Cardinal Health (NYSE: CAH) reported second-quarter 2020 non-GAAP EPS attributable to the company of $1.52 vs. $1.22 expected. — Revenue increased 5% to $39.7 billion vs. $39.43 billion expected. — GAAP EPS attributable to the company decreased to $0.75 from $0.93 in the second quarter of 2019. — For FY20, Cardinal Health lifted non-GAAP […]
· February 6, 2020
— Cardinal Health (NYSE: CAH) reported second-quarter 2020 non-GAAP EPS attributable to the company of $1.52 vs. $1.22 expected.
— Revenue increased 5% to $39.7 billion vs. $39.43 billion expected.
— GAAP EPS attributable to the company decreased to $0.75 from $0.93 in the second quarter of 2019.
— For FY20, Cardinal Health lifted non-GAAP EPS attributable to the company outlook to a range of $5.20 to $5.40 from the previous range of $4.85 to $5.10.
— Pharmaceutical segment revenue increased 6% year-over-year to $35.7 billion.
— Medical segment revenue was flat with prior-year-quarter at $4 billion.
— CAH stock rose about 6% in the pre-market trading session.
